Docetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction for targeted tumor

Yue Zhang1, Ruijiao Chang1, Muqiong Li2

  • 1Department of Ultrasound, Xijing Hospital.

Oncotargets and Therapy
|August 19, 2016
PubMed
Abstract

Insights

Ultrasound-targeted destruction of docetaxel-loaded lipid microbubbles (DLLM) effectively reduced liver cancer cell proliferation and induced apoptosis. This novel targeted therapy also inhibited tumor growth in mice.

Area of Science:

  • Oncology
  • Biotechnology
  • Nanomedicine

Background:

  • Targeted drug delivery remains a significant challenge in cancer therapy.
  • Ultrasound-targeted destruction of drug-loaded lipid microbubbles (LMs) presents a promising approach.
  • This study investigated the antitumor effects of docetaxel-loaded LMs (DLLM) combined with ultrasound-targeted microbubble destruction (UTMD) in liver cancer.

Purpose of the Study:

  • To evaluate the efficacy of DLLM combined with UTMD against liver cancer cells and solid tumors.
  • To assess the impact of DLLM + UTMD on cancer cell viability, proliferation, cell cycle, and apoptosis.
  • To determine the therapeutic potential of this targeted drug delivery system in a preclinical liver cancer model.

Main Methods:

  • Docetaxel-loaded lipid microbubbles (DLLMs) were prepared using mechanical vibration.
  • In vitro studies assessed cell viability, proliferation, cell cycle, and apoptosis of liver cancer cells (MHCC-H and HepG2) exposed to docetaxel, DLLM, and DLLM + UTMD.
  • In vivo studies utilized solid tumor mouse models, comparing DLLM + UTMD treatment with a control group (blank LM + UTMD).

Main Results:

  • DLLMs exhibited a drug-loading capacity of 18%±7% and an encapsulation efficiency of 80%±3%.
  • DLLM + UTMD significantly decreased MHCC-H cell proliferation and increased apoptosis compared to other treatment groups.
  • DLLM + UTMD treatment led to G1 phase cell cycle arrest and a reduction in tumor volume in mice.

Conclusions:

  • DLLM + UTMD effectively inhibits liver cancer cell proliferation and induces apoptosis.
  • This combination therapy demonstrates significant antitumor effects by arresting cells in the G1 phase and reducing tumor growth.
  • DLLM + UTMD offers a novel and targeted therapeutic strategy for liver cancer treatment.